Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series

Crit Care. 2020 Jul 3;24(1):392. doi: 10.1186/s13054-020-03078-z.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Amides / therapeutic use*
  • COVID-19 / drug therapy
  • Coronavirus Infections / drug therapy
  • Critical Illness
  • Drug Therapy, Combination
  • Female
  • Guanidines / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Pyrazines / therapeutic use*
  • Treatment Outcome

Substances

  • Amides
  • Guanidines
  • Pyrazines
  • favipiravir
  • nafamostat

Supplementary concepts

  • COVID-19 drug treatment